在癌症治疗中,使用放射性核素结合的肿瘤导向载体已成为最近研究和探索的重点。要成功地击中目标,需要载体的特异性和有适当的放射性核素。肿瘤相关抗原的抗体已成为一种有价值的研究工具,并很快地从实验室过渡到临床试用。历史背景早在1906年 Ehrlich 就推测,抗肿瘤抗体可能具有作为毒性物质的载体选择性地攻击肿瘤细胞的治疗作用。约20年后,法国二位最早 In the treatment of cancer, the use of radionuclide-conjugated tumor-directed vectors has become the focus of recent research and exploration. To successfully hit the target requires the specificity of the vector and the appropriate radionuclide. Antibodies against tumor-associated antigens have become a valuable research tool and have quickly transitioned from laboratories to clinical trials. Historical background As early as 1906 Ehrlich speculated that anti-tumor antibodies may have a therapeutic role as a carrier of toxic substances to selectively attack tumor cells. About 20 years later, France’s two were the earliest